Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018

Nana Wilson, Mbabazi Kariisa, Puja Seth, Herschel Smith 4th, Nicole L Davis, Nana Wilson, Mbabazi Kariisa, Puja Seth, Herschel Smith 4th, Nicole L Davis

Abstract

Of the 70,237 drug overdose deaths in the United States in 2017, approximately two thirds (47,600) involved an opioid (1). In recent years, increases in opioid-involved overdose deaths have been driven primarily by deaths involving synthetic opioids other than methadone (hereafter referred to as synthetic opioids) (1). CDC analyzed changes in age-adjusted death rates from 2017 to 2018 involving all opioids and opioid subcategories* by demographic characteristics, county urbanization levels, U.S. Census region, and state. During 2018, a total of 67,367 drug overdose deaths occurred in the United States, a 4.1% decline from 2017; 46,802 (69.5%) involved an opioid (2). From 2017 to 2018, deaths involving all opioids, prescription opioids, and heroin decreased 2%, 13.5%, and 4.1%, respectively. However, deaths involving synthetic opioids increased 10%, likely driven by illicitly manufactured fentanyl (IMF), including fentanyl analogs (1,3). Efforts related to all opioids, particularly deaths involving synthetic opioids, should be strengthened to sustain and accelerate declines in opioid-involved deaths. Comprehensive surveillance and prevention measures are critical to reducing opioid-involved deaths, including continued surveillance of evolving drug use and overdose, polysubstance use, and the changing illicit drug market; naloxone distribution and outreach to groups at risk for IMF exposure; linkage to evidence-based treatment for persons with substance use disorders; and continued partnerships with public safety.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

    1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2018;67:1419–27. 10.15585/mmwr.mm675152e1
    1. Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS data brief, no 356. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020.
    1. O’Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the field: opioid-involved overdose deaths with fentanyl or fentanyl analogs detected—United States, July 2016–December 2018. MMWR Morb Mortal Wkly Rep 2020;69:271–3. 10.15585/mmwr.mm6910a4
    1. Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697–704. 10.15585/mmwr.mm6626a4
    1. CDC. 2019 Annual surveillance report of drug-related risks and outcomes—United States surveillance special report. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
    1. Drug Enforcement Administration. 2018 National drug threat assessment. Annual drug report; 2019. Springfield, Virginia: US Department of Justice, Drug Enforcement Administration; 2019.
    1. Guy GP Jr, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital signs: pharmacy-based naloxone dispensing—United States, 2012–2018. MMWR Morb Mortal Wkly Rep 2019;68:679–86. 10.15585/mmwr.mm6831e1
    1. Davis GG; National Association of Medical Examiners and American College of Medical Toxicology Expert Panel on Evaluating and Reporting Opioid Deaths. Complete republication: National Association of Medical Examiners position paper: recommendations for the investigation, diagnosis, and certification of deaths related to opioid drugs. J Med Toxicol 2014;10:100–6. 10.1007/s13181-013-0323-x
    1. Jones CM, Olsen EO, O’Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008–2017. Am J Public Health 2020. Epub February 20, 2020. 10.2105/AJPH.2019.305527
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1). 10.15585/mmwr.rr6501e1

Source: PubMed

3
Suscribir